Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JUNE 10, 2020

At the most basic level, a buyer wants to understand two things: (1) is there an unmet medical need such that the company’s development-stage product will substantially improve the quality of care, and (2) is there sufficient exclusivity to allow commercialization of the product. Marketing the opportunity and other process considerations.

M&A 40

M&A Medical Acquisitions Business 40

Cooley M&A

JANUARY 24, 2020

Thereafter, plaintiffs’ counsel often demands a “mootness fee” (for the alleged benefit conferred by the supplemental disclosures), over which the parties can negotiate or litigate, if necessary.

M&A 40

M&A Mergers and Acquisitions Mergers Business 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. The strong capital markets environment that has prevailed during the past few years has enabled a large number of development-stage and one?product,

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40